Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Anti-IL6R and Anticoagulation in NPC
NCT06442709Active, not recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Aug 2021
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of tocilizumab and aspirin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Affiliated Hospital of Nantong University. Primary endpoint: Tumor progression and metastasis at 10 years. Started Aug 2021; status: active, not recruiting.
02
Drugs
tocilizumabaspirin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06442709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06442709.